These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Advances in tumor vascular growth inhibition. Zhang K; Shi Y; Jin Z; He J Clin Transl Oncol; 2024 Sep; 26(9):2084-2096. PubMed ID: 38504070 [TBL] [Abstract][Full Text] [Related]
5. Anti-Angiogenics: Current Situation and Future Perspectives. Zirlik K; Duyster J Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226 [TBL] [Abstract][Full Text] [Related]
6. Angiogenesis inhibitors and the need for anti-angiogenic therapeutics. Dass CR; Tran TM; Choong PF J Dent Res; 2007 Oct; 86(10):927-36. PubMed ID: 17890668 [TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197 [TBL] [Abstract][Full Text] [Related]
8. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Shojaei F; Ferrara N Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057 [TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenesis in cancer therapy: Hercules and hydra. Bellou S; Pentheroudakis G; Murphy C; Fotsis T Cancer Lett; 2013 Sep; 338(2):219-28. PubMed ID: 23707856 [TBL] [Abstract][Full Text] [Related]
13. Is VEGF a predictive biomarker to anti-angiogenic therapy? Otrock ZK; Hatoum HA; Musallam KM; Awada AH; Shamseddine AI Crit Rev Oncol Hematol; 2011 Aug; 79(2):103-11. PubMed ID: 20724177 [TBL] [Abstract][Full Text] [Related]
14. Bevacizumab (Avastin). Mukherji SK AJNR Am J Neuroradiol; 2010 Feb; 31(2):235-6. PubMed ID: 20037132 [TBL] [Abstract][Full Text] [Related]
15. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. Lopes-Coelho F; Martins F; Pereira SA; Serpa J Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916438 [TBL] [Abstract][Full Text] [Related]
16. An Overview of Cancer Biology, Pathophysiological Development and It's Treatment Modalities: Current Challenges of Cancer anti-Angiogenic Therapy. Al-Ostoot FH; Salah S; Khanum SA Cancer Invest; 2024 Aug; 42(7):559-604. PubMed ID: 38874308 [TBL] [Abstract][Full Text] [Related]
17. Metabolic effects of anti-angiogenic therapy in tumors. Zulato E; Curtarello M; Nardo G; Indraccolo S Biochimie; 2012 Apr; 94(4):925-31. PubMed ID: 22245704 [TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy of targeting angiogenesis. Hou J; Tian L; Wei Y Cell Mol Immunol; 2004 Jun; 1(3):161-6. PubMed ID: 16219162 [TBL] [Abstract][Full Text] [Related]
19. Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment. Berndsen RH; Abdul UK; Weiss A; Zoetemelk M; Te Winkel MT; Dyson PJ; Griffioen AW; Nowak-Sliwinska P Angiogenesis; 2017 May; 20(2):245-267. PubMed ID: 28378227 [TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology of anti-angiogenic drugs in oncology. Gougis P; Wassermann J; Spano JP; Keynan N; Funck-Brentano C; Salem JE Crit Rev Oncol Hematol; 2017 Nov; 119():75-93. PubMed ID: 28916378 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]